INBX
Inhibrx Biosciences, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.91B
P/E Ratio
—
EPS
$-9.04
Beta
—
52W High
$155.29
52W Low
$10.84
50-Day MA
$77.82
200-Day MA
$59.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibrx Biosciences, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $1.30M |
| Gross Profit (TTM) | $-111.73M |
| EBITDA | $-132.54M |
| Operating Margin | -10387.00% |
| Return on Equity | -197.80% |
| Return on Assets | -51.60% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $0.55 |
| Price-to-Book | 238.79 |
| Price-to-Sales (TTM) | 1468.20 |
| EV/Revenue | 1454.96 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.61M |
| Float | $7.81M |
| % Insiders | 23.26% |
| % Institutions | 81.89% |
Historical Volatility
HV 10-Day
162.56%
HV 20-Day
129.85%
HV 30-Day
122.72%
HV 60-Day
97.26%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($300.00 target)
1
HoldData last updated: 4/29/2026